4.4 Editorial Material

Viral load monitoring in resource-limited settings: a medical and public health priority

期刊

AIDS
卷 26, 期 13, 页码 1719-1720

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QAD.0b013e3283543e2c

关键词

-

向作者/读者索取更多资源

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Public, Environmental & Occupational Health

Female Genital Mutilation/Cutting in the Swiss HIV Cohort Study: A Cross-Sectional Study

Fabio Mauri, Sara Cottler-Casanova, Matthias Cavassini, Marcel Stoeckle, Gilles Wandeler, Patrick Schmid, Dominique L. Braun, Alexandra Scherrer, Enos Bernasconi, Alexandra Calmy, Jasmine Abdulcadir

Summary: FGM/C is a harmful practice that involves injury to the female genitalia without medical purpose, and it is prevalent worldwide. There is a lack of knowledge on how to care for women with FGM/C, and improvements in care and prevention are needed.

JOURNAL OF IMMIGRANT AND MINORITY HEALTH (2023)

Article Immunology

Polygenic Risk Scores for Prediction of Subclinical Coronary Artery Disease in Persons Living With HIV: The Swiss HIV Cohort Study

Isabella C. Schoepf, Christian W. Thorball, Helen Kovari, Bruno Ledergerber, Ronny R. Buechel, Alexandra Calmy, Rainer Weber, Philipp A. Kaufmann, Rene Nkoulou, Johannes M. Schwenke, Dominique L. Braun, Jacques Fellay, Philip E. Tarr

Summary: In Swiss HIV-infected individuals, subclinical coronary artery disease is independently associated with an individual polygenic risk score for coronary artery disease. Combining non-genetic and genetic cardiovascular risk factors provides the most powerful prediction for subclinical coronary artery disease.

CLINICAL INFECTIOUS DISEASES (2023)

Article Immunology

Hepatitis B Virus (HBV) Replication During Tenofovir Therapy Is Frequent in Human Immunodeficiency Virus/HBV Coinfection

Eveline Hofmann, Bernard Surial, Noemie Boillat-Blanco, Huldrych F. Guenthard, Marcel Stoeckle, Enos Bernasconi, Patrick Schmid, Alexandra Calmy, Franziska Suter-Riniker, Andri Rauch, Gilles Wandeler, Charles Beguelin

Summary: In the Swiss HIV Cohort Study, researchers found that 27% of HIV-suppressed individuals with chronic hepatitis B virus (HBV) infection had HBV replication after two years on tenofovir. However, 77% of them were able to achieve suppression thereafter. Self-reported adherence to therapy and HBV viral load at tenofovir initiation were identified as predictors of persistent replication.

CLINICAL INFECTIOUS DISEASES (2023)

Article Immunology

Brief Report: Does Menopause Transition Influence Viral Suppression and Adherence in Women Living With HIV?

Anna Hachfeld, Andrew Atkinson, Petra Stute, Alexandra Calmy, Philip E. Tarr, Katharine E. A. Darling, Baharak Babouee Flury, Christian Polli, Leila Sultan-Beyer, Irene A. Abela, Karoline Aebi-Popp

Summary: The study found that the increased rates of depression and psychiatric care during the transition through menopause do not lead to lower levels of treatment adherence or viral suppression in women living with HIV in Switzerland.

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2023)

Article Infectious Diseases

Frequency matters: comparison of drug resistance mutation detection by Sanger and next-generation sequencing in HIV-1

Suraj Balakrishna, Tom Loosli, Maryam Zaheri, Paul Frischknecht, Michael Huber, Katharina Kusejko, Sabine Yerly, Karoline Leuzinger, Matthieu Perreau, Alban Ramette, Chris Wymant, Christophe Fraser, Paul Kellam, Astrid Gall, Hans H. Hirsch, Marcel Stoeckle, Andri Rauch, Matthias Cavassini, Enos Bernasconi, Julia Notter, Alexandra Calmy, Huldrych F. Gunthard, Karin J. Metzner, Roger D. Kouyos

Summary: This study compared the reliability of Sanger sequencing and Next-generation sequencing (NGS) in detecting HIV drug resistance mutations (DRMs). The results showed good agreement between the two methods when detecting mutations at a threshold of 5% or higher. However, at lower thresholds, NGS detected a substantial number of low-frequency mutations, which were likely to be sequencing errors.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

Article Immunology

Quantifying and Predicting Ongoing Human Immunodeficiency Virus Type 1 Transmission Dynamics in Switzerland Using a Distance-Based Clustering Approach

Marco Labarile, Tom Loosli, Marius Zeeb, Katharina Kusejko, Michael Huber, Hans H. Hirsch, Matthieu Perreau, Alban Ramette, Sabine Yerly, Matthias Cavassini, Manuel Battegay, Andri Rauch, Alexandra Calmy, Julia Notter, Enos Bernasconi, Christoph Fux, Huldrych F. Gunthard, Chloe Pasin, Roger D. Kouyos

Summary: This study investigated and predicted the dynamics of HIV transmission in Switzerland using a network-based clustering method and statistical learning approaches. The study found that network characteristics can capture major heterogeneities in transmission and that cluster structure has the potential for real-time prediction of ongoing transmission.

JOURNAL OF INFECTIOUS DISEASES (2023)

Article Immunology

Triggers of Change in Sexual Behavior Among People With HIV: The Swiss U = U Statement and COVID-19 Compared

Kalongo Hamusonde, Dunja Nicca, Huldrych F. Gunthard, Marcel Stoeckle, Katharine E. A. Darling, Alexandra Calmy, Enos Bernasconi, David Haerry, Patrick Schmid, Roger D. Kouyos, Andri Rauch, Luisa Salazar-Vizcaya

Summary: We examined the changes in sexual behavior of HIV-positive individuals over a span of 20 years. Since the Swiss U = U statement, the use of condoms with stable partners has consistently decreased from over 90% to 29%, with similar trends observed among men who have sex with men (MSM) and heterosexuals. Despite the COVID-19 pandemic and social distancing measures, MSM have maintained a higher frequency of occasional partnerships compared to heterosexual individuals.

JOURNAL OF INFECTIOUS DISEASES (2023)

Article Gastroenterology & Hepatology

Hepatitis delta infection among persons living with HIV in Europe

Charles Beguelin, Andrew Atkinson, Anders Boyd, Karolin Falconer, Nikolai Kirkby, Franziska Suter-Riniker, Huldrych F. Guenthard, Juergen K. Rockstroh, Amanda Mocroft, Andri Rauch, Lars Peters, Gilles Wandeler

Summary: A study found a high prevalence of hepatitis delta virus (HDV) infection among persons living with HIV (PLWH) in Europe, which is the most severe form of viral hepatitis. This study analyzed data from a large HIV cohort collaboration to characterize the epidemiological trends of HDV in Europe and its impact on clinical outcomes.

LIVER INTERNATIONAL (2023)

Article Multidisciplinary Sciences

Implementation and effectiveness of a linkage to HIV care intervention in rural South Africa (ANRS 12249 TasP trial)

Melanie Plazy, Adama Diallo, Thabile Hlabisa, Nonhlanhla Okesola, Collins Iwuji, Kobus Herbst, Sylvie Boyer, France Lert, Nuala McGrath, Deenan Pillay, Francois Dabis, Joseph Larmarange, Joanna Orne-Gliemann

Summary: This study reports on the implementation and effectiveness of a linkage-to-care intervention in rural South Africa, which involved tracking HIV-positive individuals through phone calls and home visits. The results showed that this intervention was effective in improving the linkage-to-care rate among patients.

PLOS ONE (2023)

Article Pharmacology & Pharmacy

Effect of SLCO1B1 c.521T>C polymorphism on the lipid response to statins in people living with HIV on a boosted protease inhibitor-containing regimen

Catia Marzolini, Matthias L. Cavassini, Dominique L. Braun, Anna Hachfeld, Enos Bernasconi, Alexandra Calmy, Patrick Schmid, Manuel Battegay, Luigia Elzi

Summary: This study aimed to investigate whether a common single polymorphism could explain the phenomenon of some HIV patients not achieving their lipid targets despite elevated statin concentrations. The study found that individuals carrying the SLCO1B1 c.521T>C polymorphism had smaller changes in lipid levels after statin initiation compared to those without this polymorphism.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2023)

Article Immunology

Understanding the Decline of Incident, Active Tuberculosis in People With Human Immunodeficiency Virus (HIV) in Switzerland

Marius Zeeb, Burcu Tepekule, Katharina Kusejko, Claudine Reiber, Marisa Kalin, Lena Bartl, Julia Notter, Hansjakob Furrer, Matthias Hoffmann, Hans H. Hirsch, Alexandra Calmy, Matthias Cavassini, Niklaus D. Labhardt, Enos Bernasconi, Dominique L. Braun, Huldrych F. Gunthard, Roger D. Kouyos, Johannes Nemeth

Summary: The incidence of tuberculosis (TB) in people with human immunodeficiency virus type 1 (HIV-1) is decreasing in Switzerland, primarily due to the control of HIV-1 infection and immune system restoration, in addition to TB-specific prevention measures.

CLINICAL INFECTIOUS DISEASES (2023)

Editorial Material Immunology

A Case of Mpox Reinfection

Stefano Musumeci, Iris Najjar, Emmanuelle Boffi El Amari, Manuel Schibler, Frederique Jacquerioz, Sabine Yerly, Adriana Renzoni, Alexandra Calmy, Laurent Kaiser

Summary: A healthy young man diagnosed with mpox in May 2022 presented with anal proctitis in November 2022 after engaging in condomless sexual intercourse with multiple male partners during a recent trip to Brazil, and tested positive for Monkeypox virus by polymerase chain reaction on a rectal swab.

CLINICAL INFECTIOUS DISEASES (2023)

News Item Virology

MOSAIC: a European cohort study of human Mpox - the challenges of clinical research in outbreaks

Sabrina Kali, Josephine Bourner, Alexandra Calmy, Cedric Laouenan, Laura Merson, Minerva Cervantes-Gonzalez, Amanda Rojek, Elise Pesonel, Laetitia Guiraud, Coralie Tardivon, Diane Descamps, Alpha Diallo, Severine Gibowski, Eric Rosenthal, Ventzislava Petrov-Sanchez, Sophie Letrou, Isabelle Hoffmann, Soizic Le Mestre, France Mentre, Yazdan Yazdanpanah, Piero Olliaro, Francois-Xavier Lescure

VIROLOGIE (2023)

Letter Immunology

Need for clear inclusion criteria in reviews of antiretroviral treatments

Alexandra Calmy, Gilles Wandeler, Matthias Egger

LANCET HIV (2023)

Article Critical Care Medicine

Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial

Marius Troseid, Jose R. Arribas, Lambert Assoumou, Aleksander Rygh Holten, Julien Poissy, Vida Terzic, Fulvia Mazzaferri, Jesus Rodriguez Bano, Joe Eustace, Maya Hites, Michael Joannidis, Jose-Artur Paiva, Jean Reuter, Isabel Puentmann, Thale D. J. H. Patrick-Brown, Elin Westerheim, Katerina Nezvalova-Henriksen, Lydie Beniguel, Tuva Borresdatter Dahl, Maude Bouscambert, Monika Halanova, Zoltan Peterfi, Sotirios Tsiodras, Michael Rezek, Matthias Briel, Serhat Unal, Martin Schlegel, Florence Ader, Karine Lacombe, Cecilie Delphin Amdal, Serge Rodrigues, Kristian Tonby, Alexandre Gaudet, Lars Heggelund, Joy Mootien, Asgeir Johannessen, Jannicke Horjen Moller, Beatriz Diaz Pollan, Anders Aune Tveita, Anders Benjamin Kildal, Jean-Christophe Richard, Olav Dalgard, Victoria Charlotte Simensen, Aliou Balde, Lucie de Gastines, Marta del Alamo, Burc Aydin, Fridtjof Lund-Johansen, Mary-Anne Trabaud, Alpha Diallo, Bente Halvorsen, John-Arne Rottingen, Evelina Tacconelli, Yazdan Yazdanpanah, Inge C. Olsen, Dominique Costagliola

Summary: The study conducted a placebo-controlled trial of baricitinib in severe/critical COVID cases. The results showed that baricitinib did not reduce mortality within 60 days, and there may be safety risks in vaccinated participants, which require further investigation.

CRITICAL CARE (2023)

暂无数据